Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupDrug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Concomitant granule cell neuronopathy in patients with natalizumab-associated PMLNatalizumab in relapsing-remitting multiple sclerosis.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.MRI pattern in asymptomatic natalizumab-associated PML.Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
P2860
Q26780412-423B66E4-9855-477A-8599-FD3AAAA69A95Q30815289-CBD07A96-6623-469B-B513-C6BBB2C85686Q35314514-C8D7A195-D319-4958-B694-F5E85BE4342BQ36352813-086BC46F-0BBA-4628-9078-F4ED4A4D809DQ36783871-E0A3D5C6-8F72-486F-A4DB-2F3369AF29F0Q38786252-24755DD0-308F-453D-B10F-3FA071AA66ECQ39211049-D6D44C75-3598-4028-ACFB-DA7017FBA63BQ40619670-482F3AAE-C6F5-41E9-A3E8-330EBE8A7880Q41048876-74C57BD1-032D-482C-95D1-CB7B2DC0D153Q41126166-88ED8E87-A4E5-4690-85D8-00A5F73C2F5BQ41361912-DDD68C95-D2F6-47BD-BF72-05696A0E2FE0Q41745436-C0D29989-6377-427C-9CB4-F1F99352C3AAQ42170814-40CE3E0C-476C-4CE2-B234-AA2B40999F22Q51100906-481453EE-77D1-4353-9900-4104A65C01D3Q52659119-6393EC4D-726E-4C3D-A9F4-F070C7A54916
P2860
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@en
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@nl
type
label
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@en
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@nl
prefLabel
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@en
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@nl
P2093
P2860
P1433
P1476
Diagnosis of asymptomatic nata ...... tween a rock and a hard place?
@en
P2093
Anke Vennegoor
Bob W van Oosten
Joep Killestein
Jop Mostert
Mike P Wattjes
P2860
P2888
P304
P356
10.1007/S00415-014-7336-5
P577
2014-04-06T00:00:00Z